SCHEMBL5218010

SCHEMBL5218010

CCCCOc1ccc(NC(=O)O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
FAAH O00519 11/20 0.62
MAPT P10636 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HPGD P15428 1/20 0.61
HTT P42858 1/20 0.61
HSD17B10 Q99714 1/20 0.61
CA12 O43570 1/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
MAPK1 P28482 1/20 0.59
ALDH1A1 P00352 1/20 0.59
S1PR1 P21453 1/20 0.58
S1PR3 Q99500 1/20 0.58
MEN1 O00255 1/20 0.58
POLB P06746 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097878 0.97 GAA (0.69) GAAL3MBTL1FAAHS1PR1S1PR3
SCHEMBL5223000 0.95 FAAH (0.70) GAAL3MBTL1FAAHS1PR1S1PR3
SCHEMBL5221933 0.95 FAAH (0.70) GAAL3MBTL1FAAHS1PR1S1PR3
SCHEMBL5215792 0.95 FAAH (0.70) GAAL3MBTL1FAAHS1PR1S1PR3
SCHEMBL5221042 0.95 FAAH (0.70) GAAL3MBTL1FAAHS1PR1S1PR3
SCHEMBL5218334 0.95 FAAH (0.70) GAAL3MBTL1FAAHS1PR1S1PR3
SCHEMBL2089631 0.95 FAAH (0.70) GAAL3MBTL1FAAHS1PR1S1PR3
SCHEMBL10074139 0.86 GAA (0.61) GAAL3MBTL1FAAHCA12CA1
SCHEMBL3223930 0.86 LMNA (0.74) GAAL3MBTL1FAAHMAPTHPGD
SCHEMBL4189931 0.85 KMT2A (0.73) FAAHMAPTKDM4EHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1472215-A4 (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-05-09 EP disclosed
US-6949574-B2 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-09-27 US disclosed
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2005-06-16 US disclosed
EP-1472215-A2 (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS Bristol-Myers Squibb Company (US) 2004-11-03 EP disclosed
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors SIT SING-YUEN (US) 2003-10-16 US disclosed
WO-2003065989-A2 (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195226-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 GAA 517/4885L3MBTL1 2799/4885FAAH 1/4885
US-20050131032-A1 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors FAAH, FAAH2, NCEH1 GAA 517/4885L3MBTL1 2799/4885FAAH 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.